Low-dose Interleukin-2 Treatment on Polymyalgia Rheumatica

Status Not yet recruiting

Clinical Trial Summary

This study aims to explore the clinical and immunological efficacy of low-dose Interleukin-2 (IL-2) on polymyalgia rheumatica.

Clinical Trial Description

The investigators designed a single center, open-label, prospective study that routinely administered low-dose IL-2 therapy to monitor the improvement of clinical and laboratory parameters to explore its efficacy and to observe changes in immune cell subsets and cytokines. One million units of Recombinant Human Interleukin-2 (rhIL-2) was administered subcutaneously five days every week for 4 weeks and then once a week for 8 weeks. All patients were followed up for 3 months after treatment. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04062006
Study type	Interventional
Source	Peking University People's Hospital
Contact
Status	Not yet recruiting
Phase	Phase 2
Start date	August 31, 2019
Completion date	June 30, 2021

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04972968` - A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154	Phase 2
Active, not recruiting	`NCT04519580` - Improved Diagnostics and Monitoring of Polymyalgia Rheumatica
Recruiting	`NCT06460142` - Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic
Terminated	`NCT03600818` - Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica	Phase 3
Completed	`NCT00836810` - Timed Release Tablet Prednisone in Polymyalgia Rheumatica	Phase 2/Phase 3
Completed	`NCT04239521` - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Completed	`NCT03263715` - A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE)	Phase 3
Recruiting	`NCT05935709` - DANIsh VASculitis Database (DANIVAS)
Not yet recruiting	`NCT02985424` - Polymyalgia Rheumatica and Giant Cell Arteritis	N/A
Completed	`NCT00138983` - Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.	Phase 3
Recruiting	`NCT06130540` - Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR	Phase 1
Recruiting	`NCT05767034` - Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)	Phase 3
Terminated	`NCT01821040` - A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR	Phase 3
Recruiting	`NCT00982332` - Efficacy of Micro-Pulse Steroid Therapy as Induction Therapy in Patients With Polymyalgia Rheumatica	N/A
Recruiting	`NCT05312944` - Polymyalgia Rheumatica Associated to Primary Sjogren Syndrome
Recruiting	`NCT04664465` - PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS
Withdrawn	`NCT02899026` - Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica	Phase 3
Recruiting	`NCT03576794` - Treatment With Leflunomide in Patients With Polymyalgia Rheumatica	Phase 3
Completed	`NCT05681676` - Melanocortin Gene Expression in Lymphocytes of Polymyalgia Patients
Recruiting	`NCT05435781` - Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency	Phase 4